Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceTWST -3.03%69 Equity-to-Asset is 0.66 as of Jun. 2026, which is 19% below its 10-year median of 0.81. GuruFocus rates TWST with a GF Score™ of 69/100 and a GF Value™ of $53.11 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,414 Biotechnology companies, Twist Bioscience ranks worse than 51.98% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Twist Bioscience's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $445.7 Mil. Twist Bioscience's Total Assets for the quarter that ended in Jun. 2026 was $672.4 Mil.
Therefore, Twist Bioscience's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.66.
The historical rank and industry rank for Twist Bioscience's Equity-to-Asset or its related term are showing as below:
TWST'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.74 Med: 0.81 Max: 0.91
Current: 0.66
During the past 10 years, the highest Equity to Asset Ratio of Twist Bioscience was 0.91. The lowest was -1.74. And the median was 0.81.
TWST's Equity-to-Asset is ranked worse than 51.98% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs TWST: 0.66
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Twist Bioscience Equity-to-Asset Related Terms
Twist Bioscience Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TWST vs QGEN, RDNT, SHC: Equity-to-Asset Comparison
For the Biotechnology subindustry, Twist Bioscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Twist Bioscience's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Twist Bioscience's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (TWST) has a Equity-to-Asset of 0.66 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Twist Bioscience and its competitors. This is 19% below median its historical median of 0.81. According to the industry distribution chart, Twist Bioscience ranks #735 out of 1414 companies in the Biotechnology industry, placing it in the top 52%.
Is Twist Bioscience's Equity-to-Asset too high?
Twist Bioscience's current Equity-to-Asset of 0.66 is 19% below median its 10-year median of 0.81. The Biotechnology industry median Equity-to-Asset is 0.68. Twist Bioscience's value of 0.66 is 2.9% below this industry median. Based on the distribution chart, Twist Bioscience ranks #735 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Equity-to-Asset compare to QGEN and RDNT?
According to the Biotechnology industry distribution chart, Twist Bioscience ranks #735 out of 1414 companies for Equity-to-Asset. This places Twist Bioscience in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Twist Bioscience's value of 0.66 is 2.9% below this benchmark. While the company's 10-year median is 0.81 vs. the industry median of 0.68, Twist Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Twist Bioscience's current Equity-to-Asset of 0.66 is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Twist Bioscience and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Twist Bioscience's current Equity-to-Asset is 0.66, which is 19% below median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.11, compared to a current price of $124.72 — trading 134.8% above its estimated fair value. The current Equity-to-Asset is 0.66, which is 19% below median its 10-year median of 0.81 and 2.9% below the Biotechnology industry median of 0.68. Twist Bioscience's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Twist Bioscience (TWST), the current Equity-to-Asset is 0.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of $124.72 is trading 134.8% above its estimated GF Value™ of $53.11.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for TWST:
Equity-to-Asset: 0.66 (19% below median its 10-year median of 0.81)
GF Value™: $53.11 vs. price of $124.72 (134.8% above fair value)
Industry Position: 2.9% below the Biotechnology median (#735 of 1414)
No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score
Get the complete analysis for TWST
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWST has been successfully added to your 
